Search research articles
Contact Us
Filters
Showing results (471-480 of 527) with videos related to
Page
of 53
Sort By:
Lancet (London, England)
|
February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2
Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.
Journal of Hepatology
|
March 28, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study
Changhoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, et al.
The New England Journal of Medicine
|
May 14, 2020
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S Finn, Shukui Qin, Masafumi Ikeda, et al.
NPJ Precision Oncology
|
July 9, 2020
Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells
Colin M Court, Shuang Hou, Lian Liu, et al.
British Journal of Cancer
|
February 3, 2021
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Andrew X Zhu, Richard S Finn, Yoon-Koo Kang, et al.
British Journal of Cancer
|
February 3, 2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, et al.
JHEP Reports : Innovation in Hepatology
|
January 4, 2021
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo, Peter R Galle, Giovanni Brandi, et al.
Cell Reports. Medicine
|
November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy
Yulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S Finn, Masatoshi Kudo, Ann-Lii Cheng, et al.
Page
of 53
Search research articles
Search
Showing results (471-480 of 527) with videos related to
Sort By:
Page
of 53
Lancet (London, England)
|
February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 13, 2020
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2
Masatoshi Kudo, Peter R Galle, Josep M Llovet, et al.
Journal of Hepatology
|
March 28, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study
Changhoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, et al.
The New England Journal of Medicine
|
May 14, 2020
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S Finn, Shukui Qin, Masafumi Ikeda, et al.
NPJ Precision Oncology
|
July 9, 2020
Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells
Colin M Court, Shuang Hou, Lian Liu, et al.
British Journal of Cancer
|
February 3, 2021
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Andrew X Zhu, Richard S Finn, Yoon-Koo Kang, et al.
British Journal of Cancer
|
February 3, 2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, et al.
JHEP Reports : Innovation in Hepatology
|
January 4, 2021
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo, Peter R Galle, Giovanni Brandi, et al.
Cell Reports. Medicine
|
November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy
Yulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S Finn, Masatoshi Kudo, Ann-Lii Cheng, et al.
Page
of 53